Page last updated: 2024-08-21

oxazoles and palbociclib

oxazoles has been researched along with palbociclib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agadjanian, H; Allen, JR; Aspuria, PJ; Cheon, DJ; Funari, V; Greenberg, D; Karlan, BY; Mizuno, T; Orsulic, S; Spiteri, E; Spurka, L; Taylor-Harding, B; Walsh, C; Wang, Q; Wiedemeyer, WR	1

Other Studies

1 other study(ies) available for oxazoles and palbociclib

Article	Year
Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget, 2015, Jan-20, Volume: 6, Issue:2 Topics: Animals; Cyclin E; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; E2F Transcription Factors; Female; Humans; Mice; Mice, Nude; Oncogene Proteins; Ovarian Neoplasms; Oxazoles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Proto-Oncogene Proteins p21(ras); Pyridines; Random Allocation; ras Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thiazoles; Transcription, Genetic; Xenograft Model Antitumor Assays	2015

Article

Year

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS.

Oncotarget, 2015, Jan-20, Volume: 6, Issue:2

Topics: Animals; Cyclin E; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; E2F Transcription Factors; Female; Humans; Mice; Mice, Nude; Oncogene Proteins; Ovarian Neoplasms; Oxazoles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ets; Proto-Oncogene Proteins p21(ras); Pyridines; Random Allocation; ras Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thiazoles; Transcription, Genetic; Xenograft Model Antitumor Assays

2015